Sage Journals: Discover world-class research

Abstract

Background:

MYCN gene amplification is a powerful indicator of poor prognosis of neuroblastoma patients. However, MYCN non-amplified patients still showed heterogeneity in survival outcome. This study aimed to investigate the prognostic role of MYCN immunohistochemistry (IHC) in pre-treatment and post-treatment neuroblastoma tumors.

Methods:

215 untreated neuroblastoma tumors were stained with anti-MYCN antibody by immunohistochemical staining. 22 post-treatment tumors were used to compare MYCN staining with paired pre-treatment samples. Results were analyzed with other prognostic indicators.

Results:

Moderate or strong expression of MYCN was associated with unfavorable survival outcomes (P < .001). Prominent staining of MYCN IHC was 95% sensitive and 95% specific for the presence of MYCN gene amplification in this study. Ten of 214 (5%) patients showed prominent MYCN staining but MYCN non-amplification, and had a poor prognosis (29.6 ± 16.4%, 5-year overall survival). Most of cases (7/11, 64%) with high or moderate MYCN expression before chemotherapy showed lower expression in their tumors after chemotherapy.

Conclusion:

MYCN protein overexpression was not only a sensitive and specific marker for MYCN gene amplification, but also a marker of poor prognosis in patients without MYCN amplification. However, MYCN protein expression was not always consistent before and after treatment.

Keywords

neuroblastoma MYCN immunohistochemistry FISH biomarker chemotherapy

Get full access to this article

View all access options for this article.

References

Matthay

Maris

Schleiermacher

, et al. Neuroblastoma. Nat Rev Dis Primers. 2016;2:216078.

Cohn

Pearson

London

, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report. J Clin Oncol. 2009;27(2):289-297.

Lee

Park

Kang

, et al. ALK protein expression is related to neuroblastoma aggressiveness but is not independent prognostic factor. Cancer Res Treat. 2018;50(2):495-505.

Santiago

Tarek

Boulos

, et al. Correlation between MYCN gene status and MYCN protein expression in neuroblastoma: a pilot study to propose the use of MYCN immunohistochemistry in limited-resource areas. J Glob Oncol. 2019;5:1-7.

Ambros

Brodeur

, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer. 2009;100(9):1471-1482.

Niemas-Teshiba

Matsuno

Wang

, et al. MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children’s oncology group. Oncotarget. 2018;9(5):6416-6432.

Wang

Suganuma

Ikegaki

, et al. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children’s Oncology Group. Cancer. 2013;119(20):3718-3726.

Yang

Zhao

Zhang

, et al. MYCN protein stability is a better prognostic indicator in neuroblastoma. BMC Pediatr. 2022;22(1):404.

Monclair

Brodeur

Ambros

, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG task force report. J Clin Oncol. 2009;27(2):298-303.

10.

Shimada

Ambros

Dehner

, et al. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer. 1999;86(2):349-363.

11.

Shimada

Ambros

Dehner

, et al. The international neuroblastoma pathology classification (the Shimada system). Cancer. 1999;86(2):364-372.

12.

Peuchmaur

d’Amore

Joshi

, et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer. 2003;98(10):2274-2281.

13.

Suganuma

Wang

Sano

, et al. Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children’s Oncology Group and the International Neuroblastoma Pathology Committee. Pediatr Blood Cancer. 2013;60(3):363-370.

14.

Wang

Teshiba

Ikegaki

, et al. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children’s Oncology Group study. Br J Cancer. 2015;113(1):57-63.

15.

Ambros

Hata

Joshi

, et al. Morphologic features of neuroblastoma (Schwannian stroma-poor tumors) in clinically favorable and unfavorable groups. Cancer. 2002;94(5):1574-1583.

16.

Campbell

Gastier-Foster

Mann

, et al. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: a report from the Children’s Oncology Group. Cancer. 2017;123(21):4224-4235.

17.

Kim

Lee

, et al. Comparison of next-generation sequencing and fluorescence in situ hybridization for detection of segmental chromosomal aberrations in neuroblastoma. Diagnostics. 2021;11:1702.

18.

Higashi

Sakai

Fumino

, et al. The roles played by the MYCN, Trk, and ALK genes in neuroblastoma and neural development. Surg Today. 2019;49:721-727.

19.

Chan

Gallie

DeBoer

, et al. MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res. 1997;3(10):1699-1706.

20.

Chang

Yang

, et al. The prognostic roles of and correlation between ALK and MYCN protein expression in neuroblastoma. J Clin Pathol. 2020;73(3):154-161.

21.

Chang

Tseng

, et al. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients. Mod Pathol. 2020;33(4):531-540.

22.

Nisen

Waber

Rich

, et al. N-myc oncogene RNA expression in neuroblastoma. J Natl Cancer Inst. 1988;80(20):1633-1637.

23.

Braoudaki

Hatziagapiou

Zaravinos

, et al. MYCN in neuroblastoma: “old wine into new wineskins”. Diseases. 2021;9(4):78.

24.

Molenaar

Domingo-Fernández

Ebus

, et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet. 2012;44(11):1199-1206.

25.

Otto

Horn

Brockmann

, et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell. 2009;15(1):67-78.

26.

Strieder

Lutz

. Regulation of N-myc expression in development and disease. Cancer Lett. 2002;180(2):107-119.

27.

Kawano

Hazard

Chiu

, et al. Stage 4S neuroblastoma: molecular, histologic, and immunohistochemical characteristics and presence of 2 distinct patterns of MYCN protein overexpression-a report from the children’s oncology group. Am J Surg Pathol. 2021;45(8):1075-1081.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB

Prominent Staining of MYCN Immunohistochemistry Predicts a Poor Prognosis in MYCN Non-Amplified Neuroblastoma

Abstract

Background:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material